ReviewNature reviews. Neurology2015
Clearance systems in the brain-implications for Alzheimer disease.
Review in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 969 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
969 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,605 citations in OpenAlex.
- Choroid plexus volume in Alzheimer's disease: A systematic review and meta-analysis.Journal of Alzheimer's disease : JAD · 2026Pooled it
- Glymphatic-related imaging findings in type 2 diabetes mellitus: a systematic review and exploratory meta-analysis of DTI-ALPS studies.Frontiers in aging neuroscience · 2026Pooled it
- Glymphatic dysfunction in Alzheimer's disease: a systematic review and meta-analysis of the DTI-ALPS index as an imaging biomarker.Frontiers in aging neuroscience · 2026Pooled it
- The Role of c-Abl in Alzheimer's Disease: Guilty or not Guilty?Cellular and molecular neurobiology · 2025Pooled it
- Unraveling the Role of LRP1 in Alzheimer's Disease: A Focus on Aβ Clearance and the Liver-Brain Axis.Journal of molecular neuroscience : MN · 2025Pooled it
- Effects of a Combined Vitamin DNutrients · 2026Trial
- Trial
- tDCS improves early Alzheimer's disease by synaptic vesicle fusion and release.Military Medical Research · 2026Article
- Periodontal Status and the Risk of All-Cause Dementia, Alzheimer's Disease and Vascular Dementia in a Community: The Hisayama Study.Journal of clinical periodontology · 2026Article
- Article
- Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression.Annals of neurology · 2026Article
- Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue.Nature communications · 2026Article
- Fibronectin mediates APOE4-driven blood-brain barrier dysfunction in Alzheimer's disease.Nature aging · 2026Article
- Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels.Aging cell · 2026Review
- Cochlear amyloid beta 42-mediated hearing loss: A marker of preclinical Alzheimer's disease.Neural regeneration research · 2026Article
- A Novel Hyaluronic Acid-Glycyrrhizic Acid Complex Mitigates γ-Radiation-Induced Neurotransmitter Damage in Rats.Applied biochemistry and biotechnology · 2026Article
- Cerebral venous blood flow regulates intracerebral pressure and brain clearance via meningeal lymphatic vessels.Nature neuroscience · 2026Article
- Aβ1-40 induces venular endothelial cell ferroptosis in cerebral amyloid angiopathy via the ATF3/xCT axis: Insights from single-cell RNA sequencing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Calcium dysregulation in neurovascular function in Alzheimer's disease: mechanisms, therapeutic targets.GeroScience · 2026Review
- Leptomeningeal fibroblasts promote glioblastoma progression by regulating cerebrospinal fluid dynamics.Nature communications · 2026Article
909 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
Abstract
Accumulation of toxic protein aggregates-amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles-is the pathological hallmark of Alzheimer disease (AD). Aβ accumulation has been hypothesized to result from an imbalance between Aβ production and clearance; indeed, Aβ clearance seems to be impaired in both early and late forms of AD. To develop efficient strategies to slow down or halt AD, it is critical to understand how Aβ is cleared from the brain. Extracellular Aβ deposits can be removed from the brain by various clearance systems, most importantly, transport across the blood-brain barrier. Findings from the past few years suggest that astroglial-mediated interstitial fluid (ISF) bulk flow, known as the glymphatic system, might contribute to a larger portion of extracellular Aβ (eAβ) clearance than previously thought. The meningeal lymphatic vessels, discovered in 2015, might provide another clearance route. Because these clearance systems act together to drive eAβ from the brain, any alteration to their function could contribute to AD. An understanding of Aβ clearance might provide strategies to reduce excess Aβ deposits and delay, or even prevent, disease onset. In this Review, we describe the clearance systems of the brain as they relate to proteins implicated in AD pathology, with the main focus on Aβ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.